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a b s t r a c t
Recombinant yeast pyruvate carboxylase (PYC2) expression was previously shown to be an effective
metabolic engineering strategy for reducing lactate formation in a number of relevant mammalian cell
lines, but, in the case of CHO cells, did not consistently lead to signiﬁcant improvement in terms of cell
growth, product titer and energy metabolism efﬁciency. In the present study, we report on the establish-
ment of a PYC2-expressing CHO cell line producing a monoclonal antibody and displaying a signiﬁcantly
altered lactate metabolism compared to its parental line. All clones exhibiting strong PYC2 expression
were shown to experience a signiﬁcant and systematic metabolic shift toward lactate consumption, as
well as a prolonged exponential growth phase leading to an increased maximum cell concentration and
volumetric product titer. Of salient interest, PYC2-expressing CHO cells were shown to maintain a highly
efﬁcient metabolism in fed-batch cultures, even when exposed to high glucose levels, thereby alleviating
the need of controlling nutrient at low levels and the potential negative impact of such strategy on prod-
uct glycosylation. In bioreactor operated in fed-batch mode, the higher maximum cell density achieved
with the PYC2 clone led to a net gain (20%) in ﬁnal volumetric productivity.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Whether to support new therapeutic antibody development or
to respond to market needs, the ability to cost-efﬁciently gener-
ate high yield and high quality of biotherapeutics is critical for
the biopharmaceutical industry, owing to the great pressure to
lower the cost and shorten the period between drug discovery
and product manufacturing. The development and implementa-
tion of high-yield fed-batch strategies has contributed greatly at
increasing the productivity of mammalian cell cultures (Bibila and
Robinson, 1995; Wlaschin and Hu, 2006; Wurm, 2004). In fed-
batch processes, the prolonged culture time is often associated
with signiﬁcant lactate and ammonia accumulation in the culture
medium over time, which can have detrimental impacts on cell
growth and product quality. Continuous cell lines, like CHO cells,
show a deregulated glucose metabolism associated with high lac-
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tate production that can cause medium acidiﬁcation or undesired
osmolality changes due to alkali addition for culture pH control
(Cruz et al., 2000; Lao and Toth, 1997; Omasa et al., 1991; Ozturk
et al., 1992). Ammonia iswell-known to alter the glycosylation pat-
terns of monoclonal antibodies and other glycoproteins (Andersen
and Goochee, 1995; Borys et al., 1994; Chen and Harcum, 2006;
Gawlitzek et al., 2000; Yang and Butler, 2002). Appropriate gly-
cosylation of monoclonal antibodies and recombinant proteins is
necessary to ensure their biological function and their use as ther-
apeutics. Thus, maintaining consistent and comparable product
quality in high cell density cultures remains a critical challenge.
Several waste reduction strategies have been proposed using
either metabolic or process engineering approaches. This includes
the use of nutrients replacement strategies, for example the
substitution of glucose with galactose (Altamirano et al., 2006,
2000, 2004) or pyruvate (Genzel et al., 2005) or substituting
glutamine with asparagine (Kurano et al., 1990) or glutamate
(Altamirano et al., 2000; Hassel and Butler, 1990). While effective
at reducing waste metabolite formation, these substitutions are
often associated with a concomitant reduction in cellular growth.
Reduced lactate and ammonia production during fed-batch can be
achieved by maintaining glucose and glutamine at very low levels
http://dx.doi.org/10.1016/j.jbiotec.2015.11.010
0168-1656/Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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(Omasa et al., 1992; Zhou et al., 1995). Under lownutrient availabil-
ity, the cellmetabolism is shifted toward amore efﬁcientmetabolic
state characterized by a lower molar ratio of lactate/glucose (Chee
Furng Wong et al., 2005; Maranga and Goochee, 2006). However,
this requires the constant monitoring of nutrient levels and feed
rate adjustments since non-limiting concentrations must be main-
tained at all time during the culture. Even short period of glucose
starvation were shown to alter the glycosylation of the product
(Xie et al., 1997). Moreover, it has been demonstrated that low glu-
cose concentrations (<15mM) lead to reduced site occupancy and
decreased galactosylation and sialylation of antibodies (Liu et al.,
2014). A dynamic fed-batch strategy to maintain low glutamine
(0.1–0.3mM) and glucose (0.35–0.70mM) concentrations was also
shown to decrease complex-type glycan formation and sialic acid
content (Chee Furng Wong et al., 2005). These results emphasize
the need to optimize both product titer and quality concurrently.
Different metabolic engineering approaches have also been
investigated to generate cell lines with improved metabolic char-
acteristics. The ampliﬁcation of the glutamine synthetase gene in
CHOandmyelomacells allowedgrowth inglutamine-freemedium,
thereby signiﬁcantly reducing ammonia formation (Paredes et al.,
1999; Zhang et al., 2006). Partial disruption of the gene encoding
lactate dehydrogenase A by the means of homologous recombi-
nation in hybridoma cells (Chen et al., 2001) or siRNA in CHO cells
(Jeong et al., 2006; Kim and Lee, 2007a)was shown to greatly lower
the production of lactate, as well as glucose consumption. Studies
by Chen et al. (2001) and Kim and Lee (2007a) on the down regula-
tionof LDHA led to increasedﬁnalproduct concentrations, although
cell growth remained unaffected. In contrast, Jeong et al. (2006)
observed an increased cell growth rate, but no signiﬁcant impact
on tPA production unless downregulation of LDH was combined
with the overexpression of glycerol-3-phosphate dehydrogenase.
A recent study demonstrated that the simultaneous downregula-
tion of LDH and pyruvate dehydrogenase kinase can signiﬁcantly
reduce lactate accumulation and increase the volumetric antibody
production, without impairing cell growth (Zhou et al., 2011). The
expression of anti-apoptotic genes was also found to signiﬁcantly
alter the lactate metabolism of CHO cells, inducing a metabolic
shift toward lactate consumption and increasing the ﬁnal antibody
titer by 40% (Dorai et al., 2009). Another approach consisted in the
expression of the cytosolic yeast pyruvate carboxylase 2 (PYC2)
gene in BHK (Irani et al., 1999) and HEK293 cells (Elias et al., 2003;
Henry and Durocher, 2011; Vallée et al., 2013). In all cases, lactate
formation was signiﬁcantly decreased and, depending on the cell
type and prevailing culture conditions, translated into improve-
ment of either productivity or cell growth, but not both. In the case
of CHO cells, two strategies were explored. First, the insertion of
the human pyruvate carboxylase (hPC) gene in DG44 cells, which
led to a slight decrease in lactate production (Kim and Lee, 2007b),
as this enzyme is expressed in the mitochondria and is therefore
not competing directly with LDH for pyruvate conversion. Second,
one study reported on the expression of PYC2 in CHO cells, which
allowed to decrease the speciﬁc lactate production (Fogolín et al.,
2004). However, the molar ratio of lactate/glucose remained high
(∼1.5) and relatively unchanged compared to the untransformed
cells (∼1.7), indicating that the reduction in lactate accumulation
was mostly due to a decrease in glucose uptake rate. Moreover,
while prolonged cell viabilitywas observed, thiswas at the expense
of the maximum cell density, which exhibited a 2-fold reduction
in batch culture. Recently, PYC2 overexpression in CHO cells was
shown to prolong culture longevity and reduce the lactate/glucose
ratio by 25%, but at the expense of a 50% reduction in the cell spe-
ciﬁc antibody production rate and an overall decrease in antibody
titer (Wilkens and Gerdtzen, 2015).
In the present work, we show the establishment of a PYC2-
expressing CHO cell line with a greatly improved metabolic
efﬁciency that translated into reduced lactate accumulation with-
out impairing the cells’ speciﬁc productivity. All the PYC2-
expressing clones that were generated exhibited a prolonged
exponential growth phase leading to increases in maximum cell
concentration and volumetric productivity. We also demonstrate
that the PYC2-expressing cells can maintain their improved phe-
notype during fed-batch cultures employing concentrated nutrient
solutions. In fed-batch bioreactor cultures, this resulted in further
signiﬁcant increases in terms of maximum cell density and ﬁnal
product titer.
2. Materials and methods
2.1. Stable cell line development
The CHO-EG2 clone 1A7 stably expressing a chimeric human-
llama heavy chain monoclonal antibody (EG2) against epidermal
growth factor receptor (EGFR) (Bell et al., 2010) was established
from the CHO-DUXB11 cell line (Agrawal et al., 2012). The CHO-
EG2-PYC2 clone was obtained by transfection of the CHO-EG2 cell
line with the pTT18 vector encoding the yeast pyruvate carboxy-
lase 2 gene. After transfection, hygromicin B was added to the cell
culture at a ﬁnal concentration of 900g/mL. After two weeks of
selection, the pool of hygromycin-resistant cells was cloned by
limiting dilution in 96-well plate. After 2 weeks, colonies were
expanded and screened for their PYC2 expression level by west-
ern blot. Since the PYC2 enzyme is naturally biotinylated, it allows
its detection using HRP-conjugated streptavidin (Sigma). Brieﬂy,
cells pellets were incubated on ice 20min in a lysis buffer contain-
ing 50mM HEPES pH 7.4, 150mM NaCl, 1% Thesit® (Roche), 0.5%
Na Deoxycholate, 1× complete-protease inhibitor cocktail (Roche).
Cell lysates were centrifuged for 20min at 12,000× g at 4 ◦C.
Supernatants were incubated 5min at 90 ◦C in SDS sample buffer
containing 5mM dithiothreitol. Samples were electrophoresed on
an SDS polyacrylamide gel electrophoresis (PAGE) and transferred
onto a nitrocellulose membrane (Schleicher & Schuell). Mem-
branes were probed with HRP-conjugated streptavidin (Sigma).
An anti-GAPDH rabbit polyclonal antibody (Sigma) was utilized
for detection of the GAPDH to control total protein load. As
a secondary antibody, an anti-rabbit polyclonal antibody HRP-
conjugated (sigma) was employed. The blots were developed using
a chemiluminescence kit (Boehringer Mannheim, Germany) and
visualized with the Kodak imager system 440CF.
2.2. Fed-batch culture in shake ﬂasks for clone evaluation
Eleven PYC2-positive clones and 4 PYC2-negatives clones were
cultivated in 250mL shake-ﬂasks. After 4 days of cultivation, glu-
cosewasaddeddaily inorder tomaintaina concentrationof20mM.
Lactate formation was measured daily for phenotypic screening to
conﬁrm that the change in lactate metabolism was the results of
PYC2 overexpression rather than clonal effect.
2.3. PYC2 cytosolic expression
Three clones were selected according to their stable expression
of PYC2. In order to conﬁrm cytosolic PYC2 expression, the cytosols
of these clones were isolated using mitochondria isolation kit for
cultured cells (Thermo Scientiﬁc- cat#89874). Their PYC2 expres-
sion level was assessed by western blot using HRP-conjugated
streptavidin (Sigma) as described before.
2.4. Medium and culture conditions
PowerCHO2 chemically deﬁnedmedium (Lonza) supplemented
with 8mM glutamine, 0.1% Kolliphor® (Sigma) and 2% (v/v) anti
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clumping agent (Gibco) was used for stable cell line development
and batch shake-ﬂasks experiments. Cultures were inoculated at
a cell concentration of 0.2×106 cells/mL and were grown at 37 ◦C
and 5% CO2 under constant agitation (120 rpm).
2.5. pH monitoring in 6-well plates
Cell cultures were inoculated at a cell concentration of 0.2×106
cells/mL and grown at 37 ◦C and 5% CO2 under constant agitation
(120 rpm) in6-well plateswith integratedpHsensors (HydroDish®,
PreSens-Precision Sensing GmbH, Germany).
2.6. Fed-batch cultivation
For fed-batch cultivation in shake ﬂask or bioreactor, cells
were seeded at a target cell concentration of 0.2×106 cells/mL in
BalanCD (Irvine) chemically deﬁned medium supplemented with
8mM glutamine, 0.1% Kolliphor® and 2% (v/v) anti clumping agent
(Gibco). Samples were taken daily to measure the cell density and
nutrient/metabolite concentrations. Once the analyses completed,
addition of CHO CD EfﬁcientFeedTM B (Gibco) supplemented with
40mMof glutaminewas performed on a daily basis. The daily feed-
ing volume is calculated according to the cell speciﬁc consumption
of glucose:
FeedVolume =
(
R × IVCDpredicted
)
−
(
Ct × V − Ctarget × V
)
Cfeed
where R denotes the speciﬁc nutrient consumption rate. Ct and
Ctarget are the nutrient concentration and the desired nutrient con-
centration, respectively. V denotes the volume of the vessel and
Cfeed represents the nutrient concentration in the feed.
2.7. Bioreactor
Bioreactor experimentswere performed in 2 L stirred bioreactor
(Labfors 4 cell, Infors HT, Switzerland) operated at a 0.6 L starting
volume. Dissolved oxygen was maintained at 50% of air saturation
by surface aeration using a gasmixture of oxygen/nitrogen/airwith
a gas ﬂow set at 100mL/min. When necessary, pure oxygen was
spargedat2mL/minwithanon/off controller. The temperaturewas
maintained at 37 ◦Cwith a double-wallwater-jacketed. The stirring
speed started at 80 rpmandwas gradually increased during culture
to reduce cell clumping andoptimize gas transfer, until amaximum
of 120 rpm. Culture pH was controlled at 7.0 by a surface gassing of
CO2 or 1Msodiumhydroxide addition. Additionof feedingmedium
wasoperatedwith adigital tubingpumpdelivering thedesired feed
volume at a ﬂow rate of 280L/min.
2.8. Analytical methods
2.8.1. Cell count and viability, glucose, lactate, ammonium,
glutamine quantiﬁcation
Cell number and viability were assessed by trypan blue exclu-
sion and counting on a hemocytometer. Samples were centrifuged
and the supernatantswere frozenat−80 ◦C for subsequentanalysis.
The glucose, lactate and glutamine concentrations in supernatants
were measured with YSI 2700 Select biochemistry analyzer (Yel-
low Spring, USA). Ammonia concentration was measured by the
VITROS 350 (Orthoclinical Diagnostics, USA).
2.8.2. Antibody quantiﬁcation
Antibody quantiﬁcation in supernatants was determined by
high performance liquid chromatography (WATERS Corporation,
Milford, MA) using a protein A cartridge (POROS® A20 column,
2.1mmD×30mmH,104L, Invitrogen,Grand Island,NY). Samples
Fig. 1. Generation of a stable cell line expressing PYC2. (A) Example of western
blot analysis of CHO cells transfected with the PYC2 gene. PYC2 and PC expression
levels are detected using HRP-conjugated streptavidin. Lane 1: parental cell line
(untransfected), lanes: 2, 4, 7, 24: PYC2 positive clones. Lanes: 3, 5, 6–23, 25: PYC2
negative clones. (B) Western blot of the 11 PYC2 positive clones chosen for batch
cultivation. (C) Western blot of the 3 PYC2 clones exhibiting overexpression of PYC2
after 2month in culture (D)Western blot analysis of PYC2 expression in the cytosolic
fraction. Lanes 1–3: PYC2 positive clones. Lane 4: parental cell line (untransfected).
were ﬁltered by centrifugation at 8000–11,000× g for 3min using
NANOSEP MF GHP 0.45m centrifugal devices (PALL Life Sciences)
prior to being injected on the column at a ﬂow rate of 2mL/min
(PBS) and elution was performed using 0.15M NaCl, pH 2.0. UV
detection was done at 280nm.
3. Results
3.1. Generation of CHO clones overexpressing PYC2
The pTT18 vector encoding the yeast pyruvate carboxylase 2
gene was transfected in CHO cells stably expressing a chimeric
human-llama heavy chain monoclonal antibody (EG2). 129 indi-
vidual clones were assessed for their level of PYC2 expression
by western blot (Fig. 1A). For the parental cell line (Lane 1), the
observed signal corresponds to the presence of the endogenous
pyruvate carboxylase (PC) naturally expressed in the mitochon-
dria of cells and which bears the same apparent molecular weight.
PYC2-expressing clones (e.g., lanes 2, 4, 7 and 24 in Fig. 1A) all dis-
played a stronger signal reﬂecting the combined expression of PC
and PYC2. Clones transfected with the pTT18 vector but showing a
signal similar to the parental cells (e.g., lanes 3, 5, 6, 8–23 and 25 in
Fig. 1A) were considered as negative. Finally, 11 clones that exhib-
ited signiﬁcant PYC2 expression were selected and used for further
analysis (Fig. 1B). Given that PYC2 is expected to be expressed
in the cytosol (in contrast to endogenous PC that is localized in
the mitochondria), a subcellular fractionation was performed on
three PYC2-positive clones (clones 1, 7 and 11 from Fig. 1C) that
were selected on the basis of their stable PYC2 expression for over
2 months in culture. As shown in Fig. 1D, western blot analysis
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Fig. 2. (A) Lactate and (B) viable cell concentration proﬁles for PYC2 clones com-
pared to PYC2 negative clones and the parental cell line cultivated in shake-ﬂask
cultures.
revealed a signal corresponding to PYC2 that was indeed speciﬁc to
the transfected clones and conﬁrmed its proper expression in the
cytosol. As expected, GAPDH expression was observed in all the
cytosolic fractions.
3.2. Phenotypic evaluation of PYC2 clones
To rapidly assess the impact of PYC2 expression on cell growth
and metabolism, 11 PYC2-positive clones were cultivated in shake
ﬂasks operated in fed-batch mode, whereby glucose was added on
a daily basis to maintain a target concentration of 20mM. Main-
taining glucose in excess was used to create conditions favoring an
overﬂow metabolism (i.e., lactate production) and to avoid limita-
tions that could alter lactate metabolism as reported in previous
studies (Altamirano et al., 2006; Martínez et al., 2013). To rule out
potential effects attributable to clonal variation, the kinetics of cell
growth and lactate production of the 11 PYC2-positive clones were
evaluated and compared to that of the parental cell line and to 4
PYC2-negative clones that were randomly chosen to serve as neg-
ative controls. As shown in Fig. 2A and in striking contrast with
the negative clones and the parental cells, all the PYC2-expressing
clones exhibited the same altered metabolism characterized by a
signiﬁcant shift towards lactate consumption around day 6. Note-
worthy, cell growth was not negatively impacted and most of the
positive clones even reached slightly higher maximum viable cell
concentrations (Fig. 2B).
Several studies have previously shown that the culture medium
composition can strongly inﬂuence the metabolism of a given
cell line, including its pattern of lactate production/consumption
(Altamirano et al., 2006; Luo et al., 2012; Ma et al., 2009; Yuk
et al., 2014; Zagari et al., 2013a). In order to conﬁrm the consis-
tency of the metabolic shift displayed by the PYC2 clones, cells
Fig. 3. (A) Final lactate and (B) ammonia concentrations for PYC2 and parental
cell lines cultivated in 4 different media in shake-ﬂask cultures. Error bars depict
standard deviations of the measurements. ND: medium not tested for clones 1 and
2.
Fig. 4. Evolution of pH for the parental cell line and3PYC2positive clones cultivated
in 6 well plates equipped with pH sensors (HydroDish®). The 3 pH peaks indicated
by arrows correspond to sampling of the cultures.
were cultivated in 5 commonly used commercial media. As shown
in Fig. 3A, the ﬁnal lactate concentrations varied depending on the
culture medium, but were always consistently lower in the case
of the PYC2-expressing clones compared to the parental cells. It
should be emphasized that the differences observed were not the
result of signiﬁcant changes in cell densities, as the calculated cell
speciﬁc lactate production rates were also consistently lower for
PYC2 clones compared to the parental cell line (data not shown).
Of salient interest, signiﬁcant reductions in ﬁnal ammonia concen-
trations (up to 50%) were also observed for PYC2 clones in three of
the ﬁve commercial media formulation tested (Fig. 3B).
Lactate accumulation and the consequent medium acidiﬁcation
in uncontrolled ﬂask cultures can be detrimental to the cells and/or
the product quality. We therefore investigated the impact of PYC2
expression on the evolution of pH. To that end, cellswere cultivated
in batch mode in a 6-well plates and pH was monitored using a
sensor dish reader (SensorDish®). The recorded pH signals are pre-
sented in Fig. 4 and clearly demonstrate that the acidiﬁcation of the
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Fig. 5. (A) Cell density, (B) cell viability, (C) glucose, (D) lactate, (E) glutamine and (F) ammonia concentration proﬁles during batch and fed-batch cultivations of parental
and PYC2-expressing cells in shake-ﬂask cultures. Error bars depict standard deviations of the measurements.
medium is signiﬁcantly reduced in cultures performed with PYC2
clones.
3.3. Batch and fed batch cultivations in shake ﬂasks
In order to assess the potential of PYC2 clones for fed-batch
applications, cells were cultivated in shake ﬂasks under batch and
fed-batch modes using the BalanCD medium, which yielded the
highest cell density in shake ﬂask batch cultures. Clone #11 (Fig. 1)
was used in all the subsequent experiments in shake ﬂask and
bioreactor cultures. The resulting cell density proﬁles are shown
in Fig. 5A for both the parental and PYC2-expressing cells. When
cultivated in batch mode, the growth curves differed markedly
between both cell lines. The PYC2 cell line reached a maximum
cell concentration of about 1×107 cells/mL, a nearly two-fold
increase compared with the parental cells. The maximum cell spe-
ciﬁc growth rates were also fairly different for the two cell lines
(0.033 and 0.023h−1 for the PYC2 and the parental clones, respec-
tively) and the exponential phase of the PYC2 clone was extended
by more than 24h. Upon reaching their maximum cell density on
day 6, the PYC2 cells exhibited a sharp decrease in viable cell con-
centration thereafter (Fig. 5B). This suddendrop in cell viabilitywas
most likely due to a key nutrient depletion given the high cell den-
sity reached in these batch cultures. When grown in fed-batch, the
PYC2 cells had a similar cell speciﬁc growth rate (0.032h−1), but
the feeding strategy allowed to maintain high cell densities over
a prolonged period of time, as the cell viability decreased below
85% only after day 7. In contrast, the same feeding regime had only
marginal impact on the growth and viability of the parental cells
(Fig. 5A & B) compared with the batch mode.
Batch cultures were characterized by a nearly total depletion of
glucose by day 8 for both PYC2 and parental cells (Fig. 5C), while
the fed-batch strategy allowed to maintain glucose around the tar-
get concentration of 35mM. Noteworthy, despite those elevated
glucose concentrations, the PYC2 clone exhibited the same altered
lactate metabolism witnessed in batch (Fig. 5D). A comparison of
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Table 1
Cell speciﬁc consumption/production rates in shake ﬂask cultures.
Batch Fed-batch
Exponential phase PYC2 Parental PYC2 Parental
qglucose (pmol/cell.d) 1.00 ± 0.17 1.24 ± 0.21 1.18 ± 0.19 1.65 ± 0.30
qglutamine (pmol/cell.d) 0.35 ± 0.06 0.37 ± 0.07 0.47 ± 0.08 0.53 ± 0.09
qlactate (pmol/cell.d) 0.46 ± 0.06 0.98 ± 0.18 0.54 ± 0.09 1.18 ± 0.21
qammonia (pmol/cell.d) 0.57 ± 0.10 0.86 ± 0.18 0.93 ± 0.20 1.31 ± 0.28
Lactate/glucose ratio 0.46 0.79 0.46 0.72
Ammonia/glutamine ratio 1.63 2.32 1.98 2.47
Stationary phase
q glucose (pmol/cell.d) 0.69 ± 0.10 1.19 ± 0.21 1.42 ± 0.24 1.73 ± 0.29
q glutamine (pmol/cell.d) – – 0.27 ± 0.05 0.31 ± 0.05
q lactate (pmol/cell.d) −0.36 ± 0.06 −0.05 ± 0.01 −0.15 ± 0.03 −0.03 ± 0.01
q ammonia (pmol/cell.d) – – 0.41 ± 0.09 0.36 ± 0.08
Lactate/glucose ratio −0.52 −0.04 −0.11 −0.02
Ammonia/glutamine ratio – – 1.52 1.16
the main cell speciﬁc consumption and production rates evaluated
during the exponential and the stationary phases is presented in
Table 1. In batch and fed-batch cultures, only slight reduction in
the glucose speciﬁc consumption rates were observed for PYC2
cells, but marked differences were noted for lactate as the spe-
ciﬁc production was reduced by 50% during the exponential phase.
The differences were even greater during the stationary phase, as
lactate was signiﬁcantly consumed by PYC2 cells, unlike in the
parental cell line (Table 1). As evident from the calculated lac-
tate/glucose ratios, the PYC2 clone exhibited a much more efﬁcient
glucose utilization.
In batch cultures, glutamine depletion occurred rapidly (by
day 4), but the average cell speciﬁc glutamine consumption rates
were not signiﬁcantly different for the two cell lines (Fig. 5E
& Table 1). The supplementation of glutamine in fed-batch cul-
tures led to an increased consumption rate and greater ammonia
Fig. 6. (A) Cell viability, (B) cell density, (C) glucose, (D) lactate (E) glutamine and (F) ammonia concentration proﬁles fed-batch cultivations of parental and PYC2 expressing
clones in bioreactor cultures. Error bars depict standard deviations of the measurements.
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Table 2
Cell speciﬁc consumption/production rates in bioreactor cultures.
Exponential phase Stationary phase
PYC2 Parental PYC2 Parental
qglucose (pmol/cell.d) 2.46 ± 0.42 2.49 ± 0.44 1.57 ± 0.27 2.06 ± 0.33
qglutamine (pmol/cell.d) 0.75 ± 0.12 1.18 ± 0.20 0.44 ± 0.08 0.56 ± 0.09
qlactate (pmol/cell.d) 0.43 ± 0.07 2.34 ± 0.41 −0.17 ± 0.03 0.24 ± 0.04
qammonia (pmol/cell.d) 0.31 ± 0.05 1.11 ± 0.18 0.19 ± 0.03 0.24 ± 0.02
Lactate/glucose ratio 0.17 0.79 -0.11 0.11
Ammonia/glutamine ratio 0.41 0.94 0.43 0.82
Fig. 7. Comparison of maximum antibody titers between parental and PYC2-
expressing cells cultivated in shakeﬂasks andbioreactors. Error bars depict standard
deviations of the measurements.
accumulation, particularly for the PYC2 clone due to the greater
cell density and the prolonged culture. While the speciﬁc produc-
tions were quite similar during the exponential phase, both cell
lines showed a decreased production of ammonia per cell during
the stationary phase (Table 1). Whether the cultures were per-
formed in batch or fed-batch modes, the ﬁnal product titer in
cultures with PYC2-expressing cells was 35% greater compared to
the parental cell line (Fig. 7). This augmentation canbe attributed to
both the increased cell density and the prolonged culture longevity
associated with PYC2 expression. The cell speciﬁc productivity
of PYC2-expressing cells was comparable in batch and fed-batch
modes (1.91±0.40 and 2.02±0.44pg/cell day, respectively), while
that of the parental clone increased from 1.69±0.35 pg/cell day
in batch to 2.69±0.54pg/cell day in fed-batch. Compared to the
parental cell line, the slightly lower cell speciﬁc productivity of the
PYC2 clone is largely compensated by the increased cell growth.
3.4. Fed-batch cultivation in bioreactor
The sharp and sudden viability decrease witnessed in shake
ﬂasks suggested that these uninstrumented culture conditions
could not support the high cell densities reached by PYC2 cells
(around 1×107 cells/mL). Cells were thus cultivated under fed-
batchmodeusing fully controlledbioreactors soas toprovidebetter
regulated conditions in terms of pH and oxygen. The feeding strat-
egy consisted in the daily addition of a concentrated solution (CHO
CD EfﬁcientFeed B) supplemented with 40mM of glutamine. The
resulting cell densityproﬁles are shown in Fig. 6A. ThePYC2cell line
reached a maximum cell concentration of about 1.3×107 cells/mL,
a more than 2-fold increase compared with the parental cells. The
maximum cell speciﬁc growth rates were fairly similar for the two
cell lines (0.023 and 0.024h−1 for the PYC2 and the parental clones,
respectively), but the exponential growth phase was extended by 3
days in the case of the PYC2 clone. Upon reaching theirmaximum in
concentrationbetweendays9 and12 (13×106 cells/mL), therewas
a sharp decrease in viable cell density, similar to the trend observed
in small-scale cultures (Fig. 6B). Since the dissolved oxygen set-
point was successfully maintained at around 50% throughout the
culture, this was likely due to some other nutrient limitation.
As was observed in shake ﬂask cultures, the expression of the
PYC2gene led to a signiﬁcant alterationof the cellmetabolism,with
lactate being consumed after 7 days of cultivation despite elevated
glucose concentration (Fig. 6C & D). The greater nutrient utiliza-
tion efﬁciency of the PYC2 cell line was even observed during the
exponential phase, as the cell speciﬁc lactate production rate was
reducedby80% fora comparableglucoseuptake rate (Table2). PYC2
expression did not signiﬁcantly impact the glutamine metabolism,
and, as a result, the cultures achieved similar ﬁnal levels of ammo-
nia (Fig. 6E & F), although the speciﬁc ammonia production rate of
the PYC2 clone was lower (Table 2).
Consistent with small-scale fed-batch results, the average cell
speciﬁc antibody production rates was slightly lower for the PYC2
clone (2.21±0.45 and 2.86±0.58 pg/cell day for PYC2 and parental
cells), but the ﬁnal product titer was augmented by 28% due to the
higher cell density achieved (Fig. 7). Of interest, the maximum vol-
umetric titer was reached 4 days earlier in cultures with the PYC2
cells. While the fed-batch strategy brought only a slight antibody
volumetric productivity improvement in shake ﬂasks, cultures in
bioreactor improved by around 30–40% the volumetric production
of PYC2 and parental cell lines, respectively.
4. Discussion
The aim of this work was to generate a PYC2-expressing CHO
cell linewith an improvedmetabolic efﬁciency and demonstrate its
potential for the development of a fed-batch process for antibody
production. In anymetabolic engineering strategy, clonal variations
should be considered when trying to assess the real impact of gene
overexpression. Clone-based studies often fail to establish a rela-
tionship between transgene expression and the desired trait. In the
speciﬁc caseof lactate reduction strategies, a varietyof other factors
may cause differences in metabolic phenotypes, such as changes in
the medium composition (Kishishita et al., 2015; Luo et al., 2012;
Zagari et al., 2013a). In our study, we have initially compared the
kinetics of growth and metabolite formation of 11 PYC2-positive,
4 PYC2-negative and the parental clones. The fact that all 11 PYC2-
positive clones exhibited comparable phenotypes when tested in
different media formulation provided strong evidence that the dif-
ferences observed were due to PYC2 expression and not to clonal
variations.
The PYC2 expressing CHO cells that were generated displayed
a much more efﬁcient metabolism characterized by a lower
lactate/glucose ratio, especially in fed-batch cultures using an
enriched nutrient solution. More importantly, the slightly lower
cell speciﬁc antibody production of the PYC2 clone is largely com-
pensated by the increase in maximum cell density, translating
into a net gain in volumetric productivity. PYC2 expressing cells
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maintained their distinctive phenotype, even when exposed to
high glucose levels during fed-batch cultures. In addition, the cell
speciﬁc productivity is not signiﬁcantly altered by the metabolic
modiﬁcation, as was previously observed when the same gene
was overexpressed in HEK293 cells producing interferon in batch
(Henry and Durocher, 2011) or fed-batch (Vallée et al., 2013) cul-
tures. In contrast with our results, an apparent two-fold increase
in speciﬁc productivity was observed in PYC2 transfected BHK-21
cells producing recombinant EPO, although these cells were culti-
vated in perfusion mode under limiting glucose conditions (Irani
et al., 2002). However, no positive impacts were observed in terms
of maximum cell density and cell speciﬁc growth rate. Similarly,
a two-fold increase of speciﬁc hGM-CSF productivity was noted
for CHO cells expressing PYC2 cultivated in batch and following a
temperature switch (Fogolín et al., 2004). The cell speciﬁc growth
rate andmaximumcell densitywere reduced, but culture longevity
was extended leading to a rise in ﬁnal product titer. In an earlier
study, HEK293 expressing PYC2 showed no signiﬁcant increase in
SEAP titer in spite of increase cell longevity and reduced waste
production (Elias et al., 2003). Similarly, a decrease in the speciﬁc
antibody productivity was found for CHO cells expressing PYC2,
even though the cell growth rate and glucose/lactate ratio were
improved (Wilkens and Gerdtzen, 2015). Taken together, these
results indicate that the effects of PYC2 expression are dependent
on the cell type and the culture conditions. In the present study, the
greatest impact of PYC2 expression in CHO cells was on the max-
imum cell density attained during the cultures. Results from our
shake ﬂask and bioreactor cultures in fed-batch mode showed that
the increase in cumulativeviable cell concentration, combinedwith
the maintenance of antibody speciﬁc productivity, resulted into a
net increase in the ﬁnal volumetric titer.
In the transition from small-scale to bioreactor, the metabolism
and growth of the PYC2 clone remained mostly similar, but the
product titer increased substantially. This titer improvement can
likely be attributed, at least in part, to tightly regulated conditions
in the bioreactor. In the case of PYC2 cells, regardless of the cul-
ture mode (batch or fed-batch) or culture device (shake ﬂask or
bioreactor), the lactate shift seemed to occur systematically 24h
before reaching the maximal cell density, as the cells entered the
deceleration phase. For the parental CHO cell line, the net accumu-
lation of lactate ceased when cell growth stopped. In either of the
two cell lines, these results suggest a link between a certain lactate
level, growth rate reduction and lactate production shutdown. In
thecaseof cells expressingPYC2, theenzymecouldhaveanadditive
effect leading to a net lactate consumption due to the competition
forpyruvatebetween this enzymeand lactatedehydrogenase (Irani
et al., 1999). Lactate consumption has been reported to occur under
low glucose concentrations (Altamirano et al., 2004; Cruz et al.,
2000; Ozturk et al., 1992) or under non-limiting levels (Luo et al.,
2012; Ma et al., 2009; Mulukutla et al., 2012; Ozturk et al., 1997;
Pascoe et al., 2007). The co-consumption of lactate and glucosewas
identiﬁed as a highly desirable trait for industrial cell lines, since it
is typically associated with increased culture longevity and greater
product yields (Le et al., 2012). This phenomenon and its under-
lying physiological mechanisms are still not fully understood and,
consequently, not yet well-controlled. Recently, some studies have
suggested that the copper level in the culture medium could be a
trigger of lactate consumption (Luo et al., 2012; Yuk et al., 2014),
but other factors have also been associated to this metabolic shift,
including an increase in oxygen consumption, a reduction of gly-
colysis and glutaminolysis, as well as cell growth slowdown (Luo
et al., 2012; Ma et al., 2009; Mulukutla et al., 2012; Pascoe et al.,
2007).
Studies on BHK-21 expressing PYC2 have reported increases in
oxygen uptake and intracellular ATP pool, pointing to an enhanced
TCA activity resulting from this genetic modiﬁcation (Irani et al.,
1999). More recently, 13C metabolic ﬂux analysis conducted on
HEK293-PYC2 expressing cells conﬁrmed an increase in the pyru-
vate ﬂux to oxaloacetate (Henry and Durocher, 2011), although
this intermediate metabolite can subsequently have multiple fates.
First, in the cytosol, the latter can be accumulated or could be con-
verted intomalate through cytosolicmalate dehydrogenase (MDH)
with the concomitant release of NAD+. Then the malate can be
recycled intopyruvatevia cytosolicmalic enzymeorenter themito-
chondria via themalate/aspartate shuttle tobe completely oxidized
in the TCA. A previous study on CHO cells expressingmitochondrial
MDH II reported enhanced glycolysis, reduced lactate secretion and
elevated intracellular ATP/NADH levels along with antibody titer
improvement (Chong et al., 2010). These ﬁndings suggest a criti-
cal role of the redox balance in the regulation of the glycolytic ﬂux
and the proportion of pyruvate entering the TCA. The capacity of
the LDH reaction to regenerate NAD+ allows to maintain high gly-
colytic rates, decreasing the availability of cytosolic pyruvate as
a substrate for the TCA cycle. The malate-aspartate shuttle plays
a pivotal role in maintaining the redox balance by allowing the
regeneration of NAD+ in the cytosol. In CHO cells, overexpression
of aralar1, an aspartate/glutamate carrier and critical component of
the malate-aspartate shuttle, was shown to promote a metabolic
switch to lactate consumption without any reduction of the gly-
colytic rate (Zagari et al., 2013b). For PYC2 overexpression, it can
be speculated that the reduction in the LDH ﬂux is likely compen-
sated by an increase in the malate dehydrogenase ﬂux to maintain
the redox balance.
The distinctive phenotype of PYC2-expressing CHO cells can
provide additional beneﬁts in the context of the development of
a cell culture manufacturing process. First, it is well known that
glycosylation pattern of glycoproteins can be negatively altered
by elevated waste product accumulation (Andersen and Goochee,
1995; Gawlitzek et al., 2000; Yang and Butler, 2002). Since signif-
icant lactate/ammonia accumulation is likely to occur in standard
highcell density fed-batchcultures, the lowerwastemetabolite for-
mation obtained in PYC2 cells could be expected to enhance ﬁnal
product quality and stability in the culture medium, but further
work is required to assess the impact of PYC2 overexpression on
product quality attributes. Furthermore, this phenotypic change
eliminates the need to control glutamine/glucose at low levels,
strategies which make process operation more complex and also
have adverse effects on the glycosylation proﬁle of the protein
of interest (Liu et al., 2014). Second, it is generally recognized
that small-scale studies performed in shake ﬂasks during process
development may not translate well to bioreactor during scale-up,
particularly due to lactate accumulation. Given that the pH changes
are damped with PYC2-expressing cells, this represents another
signiﬁcant advantage to streamline theoptimizationof culture con-
ditions.
5. Conclusion
We have demonstrated that PYC2 expression in CHO cells can
efﬁcientlyalter theirmetabolismand induceadesired shift towards
lactate consumption that was shown to occur consistently in all
culture modes and commercial media tested. Given the marked
reduction inwastemetabolite formation, the resultspresentedhere
demonstrate that PYC2 cells are well suitable for fed-batch process
employing concentrated feed solutions. Indeed, a simple feeding
strategy based on glucose consumption was able to substantially
increase culture growth and longevity and lead to a signiﬁcant
improvement of the volumetric titer. Since the cell speciﬁc pro-
ductivity of PYC2 clones was marginally reduced compared to the
parental cells, this enhancement was attributable to the signiﬁ-
cant increase inmaximumcell density. Further improvement could
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potentially be achieved by screening key culture supplements or
process conditions leading to increased culture longevity and/or
stimulating the cell speciﬁc productivity (e.g. mild hypothermia
conditions).
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